Nippon Shinyaku forecasts consolidated net profit of ¥27.0 billion for the fiscal year ending March 2027. The forecast is below the previous estimate of ¥30.3 billion, indicating a decline in profit, with the delay in approval of a new drug in the US expected to affect the second half.
Nippon Shinyaku announced a forecast for consolidated net profit of ¥27.0 billion for the fiscal year ending March 2027, down 9% from the previous fiscal year. Revenue is projected at ¥191.0 billion and operating profit at ¥33.0 billion, with both figures revised down from the previous forecasts. One factor is the delay in FDA approval of deramiocel, for which the review is continuing.
Although the company has described its plan in a way that excludes the impact of the delay in deramiocel approval, delays in the US market are weighing on its full-year outlook. Litigation and arbitration proceedings are also under way over the termination of its agreement with US partner Capricor, and the impact on earnings is being closely watched.
Uptravi is a treatment for pulmonary arterial dizziness, and the expiry of its patents could affect earnings from the fiscal year ending March 2028 onward. The company is reviewing its earnings structure in Japan and overseas and aims to adjust its overall cost base against a backdrop of higher research and development expenses.
For the April–September 2027 period, net profit fell 2% year on year to ¥15.4 billion, revenue rose 23% to ¥97.8 billion and operating profit fell 2% to ¥19.2 billion. Domestic sales of Uptravi and overseas royalty income increased, while research and development expenses, including outsourced research costs, also rose.